SCHEMBL5473602

SCHEMBL5473602

CCC(=O)c1ccc(C(=O)Nc2ccncc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
LMNA P02545 2/20 0.66
KMT2A Q03164 4/20 0.63
NT5E P21589 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
STAT3 P40763 2/20 0.62
GAA P10253 2/20 0.62
JAK2 O60674 1/20 0.62
TYK2 P29597 1/20 0.62
POLB P06746 2/20 0.59
ROCK2 O75116 2/20 0.59
ROCK1 Q13464 2/20 0.59
MAPK1 P28482 2/20 0.57
HTT P42858 1/20 0.57
CA12 O43570 1/20 0.57
CA9 Q16790 1/20 0.57
MAPT P10636 1/20 0.56
MEN1 O00255 2/20 0.54
ALDH1A1 P00352 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14716526 0.86 KDM4E (1.00) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL12228179 0.83 KDM4E (0.73) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL5459623 0.83 KDM4E (0.67) KDM4EL3MBTL1LMNAKMT2ANT5E
Methyl Alcohol SCHEMBL28281305 0.82 GAA (0.84) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL1898755 0.82 GAA (0.91) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL9696775 0.81 CACNA1B (0.67) KDM4ELMNAKMT2ASMN1; SMN2GAA
SCHEMBL13947140 0.81 KDM4E (0.81) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL5471575 0.81 KDM4E (0.81) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL30192794 0.81 TRPV1 (0.70) KDM4EL3MBTL1LMNAKMT2ANT5E
SCHEMBL19241698 0.80 KDM4E (0.88) KDM4EL3MBTL1LMNAKMT2ANT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191420-A1 Kinase inhibitors DEVGEN NV 2007-08-16 US disclosed
EP-1715862-A1 KINASE INHIBITORS Devgen NV (BE) 2006-11-02 EP disclosed
WO-2005082367-A1 KINASE INHIBITORS DEVGEN NV (BE) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191420-A1 Kinase inhibitors ROCK1, ROCK2, MAP3K20 KDM4E 569/4885L3MBTL1 2423/4885LMNA 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.